Valitor
PrivateLast Round
Series B
Oct 5, 2022
Total Funding Raised
$28M
Company Overview
Valitor is a biotechnology company that develops long-acting therapeutic proteins using a proprietary multivalent biopolymer technology platform to improve treatment outcomes in ophthalmology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Valitor Comparables
Compare Valitor with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Serina Therapeutics Inc | 81% | |
| Day One Biopharmaceuticals | 76% | |
| Sanofi | 73% |
Valitor Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 5, 2022 | ||||
| VC Round | Dec 22, 2021 |
Key People
Founding team and executive leadership
Valitor Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Berkeley Catalyst Fund | Series B, Series A |
| First Spark Ventures | Series B |
| Morningside Group | Series B |
| ExSight Ventures | Series B |
| Pandect Bioventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 3, 2026
Presenting new preclinical data at the ARVO Annual Meeting on May 3, 2026.
- Apr 13, 2026
CEO to present at the 25th Annual Needham Virtual Healthcare Conference.
Recent news
Latest coverage and updates
- attends_eventJul 15, 2026
Valitor attended event H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Jul 22nd '26.
Valitor Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Valitor's valuation, stock price, and market status.
Is Valitor a public or private company?
Valitor is a private company.
What is the current stock price of Valitor?
Valitor is a private company with no public stock price. No recent secondary market data is available.
How much is Valitor worth (valuation)?
Valuation information for Valitor is not publicly available.
Can I buy Valitor stock?
Valitor shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Valitor's last funding round?
Valitor's most recent funding round was Series B on October 5, 2022.
Who are the main investors in Valitor?
Key investors in Valitor include Berkeley Catalyst Fund, First Spark Ventures, ExSight Ventures, Pandect Bioventures.
Will Valitor IPO soon?
No public IPO plans have been announced for Valitor.
How can I track Valitor secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Valitor's secondary market activity and sign up for updates.